Skip to main content
TipRanks
Go Ultimate75% OFF

SynAct Pharma AB (SYNACT) Stock Price & Analysis

2 Followers

SYNACT Stock Chart & Stats

kr 14.32kr 1.10(8.32%)
At close: 5:30 PM GMT+1
kr 15kr 17.5kr 20Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
SEK 13.50 - SEK 14.74
52-Week Range
SEK 7.05 - SEK 24.50
Previous Close
SEK 13.22
Volume
N/A
Average Volume (3M)
108.95K
Market Cap
SEK 743.15M
Enterprise Value
SEK 986.91M
Total Cash (Recent Filing)
SEK 42.36M
Total Debt (Recent Filing)
SEK 45.53M
Price to Earnings (P/E)
―
Beta
-0.15
Next Earnings
Feb 18, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

The balance sheet’s meaningful equity base and very low debt relative to equity provide some financial flexibility while SynAct advances development. This is a durable offset to its weak earnings profile, although ongoing losses could still erode that cushion over time.

Differentiated Inflammation Approach

SynAct is pursuing a differentiated inflammation strategy intended to resolve inflammation without broadly suppressing the immune system. If clinical data support that approach, the mechanism could provide a durable basis for development and partnering interest across autoimmune indications.

Oral Lead Candidate

Resomelagon is an orally administered melanocortin receptor agonist being evaluated in rheumatoid arthritis and other inflammatory or autoimmune conditions. A single development program spanning multiple indications gives SynAct a coherent platform for creating value from clinical milestones.

Bears Say

No Commercial Revenue

The absence of reported revenue means SynAct has not yet established a commercial engine to fund research and development internally. Its financial outlook therefore remains dependent on clinical progress, external financing, or future partnering and commercialization.

Persistent Cash Burn

Persistent negative operating and free cash flow requires SynAct to keep funding development despite limited internal cash generation. Continued burn can reduce financial flexibility and increase reliance on future capital raises or other financing sources over the next several quarters.

Sustained Losses And Dilution Risk

Large recurring losses weaken returns on the existing equity base and can increase the need for additional financing. If cash requirements remain elevated, future equity issuance could dilute current shareholders and constrain the company’s ability to fund its pipeline independently.

SynAct Pharma AB News

SYNACT FAQ

What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr 7.05 and its highest was kr 24.50 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is kr 743.15M.
When is SynAct Pharma AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Nov 03, 2026. The company reported -kr 0.572 earnings per share for the quarter.
Is SynAct Pharma AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 56,213,966 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr 0.572 in its last earnings report. Following the earnings report the stock price went down -2.726%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology